Johns Hopkins HIV Guide →Drugs →Antimicrobial Agents

Valganciclovir

Paul A. Pham, Pharm.D., Kathryn Dzintars, Pharm.D., BCPS, Alice Jenh Hsu, Pharm.D.
Valganciclovir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of CMV retinitis (AIDS).
  • Prevention of CMV disease: renal, cardiac and kidney-pancreas transplant patients at high risk for CMV disease (e.g., donor positive, recipient negative).
    • Not indicated in liver transplant patients.

NON-FDA APPROVED USES

  • Prevention of disseminated CMV disease of the contralateral eye in patients treated with intraocular ganciclovir implant (no longer manufactured).

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: April 11, 2017

Citation

TY - ELEC T1 - Valganciclovir ID - 545261 A1 - Pham,Paul,Pharm.D. AU - Dzintars,Kathryn,Pharm.D., BCPS AU - Hsu,Alice,Pharm.D. Y1 - 2017/04/11/ PB - Johns Hopkins HIV Guide UR - https://www.unboundmedicine.com/medline/view/Johns_Hopkins_HIV_Guide/545261/all/Valganciclovir ER -